Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs

BACKGROUND: Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, follow...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Manag Care Spec Pharm
Egile Nagusiak: Ahuja, Vishal, Sohn, Min-Woong, Birge, John R., Syverson, Chad, Budiman-Mak, Elly, Emanuele, Nicholas, Cooper, Jennifer M., Huang, Elbert S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Academy of Managed Care Pharmacy 2015
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861222/
https://ncbi.nlm.nih.gov/pubmed/26679970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2015.21.12.1214
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak